Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease

Journal name:
Nature Reviews Nephrology
Volume:
12,
Pages:
73–81
Year published:
DOI:
doi:10.1038/nrneph.2015.173
Published online

Abstract

Chronic kidney disease (CKD) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM) and both conditions are increasing in prevalence. CKD is estimated to affect ~50% patients with T2DM globally, and its presence and severity markedly influences disease prognosis. CKD is more common in certain patient populations, including the elderly, those with youth-onset diabetes mellitus, those who are obese, certain ethnic groups, and disadvantaged populations. These same settings have also seen the greatest increase in the prevalence of T2DM, as exemplified by the increasing prevalence of T2DM in low-to- middle income countries. Patients from low-to-middle income countries are often the least able to deal with the burden of T2DM and CKD and the health-care facilities of these countries least able to deal with the demand for equitable access to renal replacement therapies. The increasing prevalence of younger individuals with T2DM, in whom an accelerated course of complications can be observed, further adds to the global burden of CKD. Paradoxically, improvements in cardiovascular survival in patients with T2DM have contributed to patients surviving longer, allowing sufficient time to develop renal impairment. This Review explores how the changing epidemiology of T2DM has influenced the prevalence and incidence of associated CKD across different populations and clinical settings.

At a glance

Figures

  1. Global incidence of type 2 diabetes mellitus (T2DM) and end-stage renal disease (ESRD).
    Figure 1: Global incidence of type 2 diabetes mellitus (T2DM) and end-stage renal disease (ESRD).

    High rates of T2DM and ESRD are found in many regions worldwide14, 124. a | Global prevalence of T2DM in adults aged 25–79 years by regions. The highest prevalence of T2DM is seen in the Middle East and North Africa. b | Estimated incidence of ESRD in patients with T2DM by regions. The highest estimated incidence of ESRD in T2DM is found in East Asia and the Pacific. ppm, patients per million.

  2. High background prevalence of renal impairment in the general population, especially in elderly individuals.
    Figure 2: High background prevalence of renal impairment in the general population, especially in elderly individuals.

    a | Prevalence of renal impairment in non-diabetic white Americans from the NHANES III study. b | Prevalence of renal impairment in non-diabetic individuals from the Australian population AUSDIAB study14, 37, 72, 124. Renal impairment is defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2.

References

  1. Zimmet, P. Z., Magliano, D. J., Herman, W. H. & Shaw, J. E. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2, 5664 (2014).
  2. Millennium Development Goals. UNDP [online], (2013).
  3. Prior, I. A. & Davidson, F. The epidemiology of diabetes in Polynesians and Europeans in New Zealand and the Pacific. N. Z. Med. J. 65, 375383 (1966).
  4. Zimmet, P., Taft, P., Guinea, A., Guthrie, W. & Thoma, K. The high prevalence of diabetes mellitus on a Central Pacific Island. Diabetologia 13, 111115 (1977).
  5. Bennett, P. H., Burch, T. A. & Miller, M. Diabetes mellitus in American (Pima) Indians. Lancet 2, 125128 (1971).
  6. Magliano, D. J. et al. Explaining the increase of diabetes prevalence and plasma glucose in Mauritius. Diabetes Care 35, 8791 (2012).
  7. Anjana, R. M. et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 54, 30223027 (2011).
  8. Mbanya, J. C., Assah, F. K., Saji, J. & Atanga, E. N. Obesity and type 2 diabetes in Sub-Sahara Africa. Curr. Diab. Rep. 14, 501 (2014).
  9. Li, R. et al. Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. Diabetes Care 35, 10281030 (2012).
  10. Jia, W. P. et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia 50, 286292 (2007).
  11. Lipscombe, L. L. & Hux, J. E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet 369, 750756 (2007).
  12. Satman, I. et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur. J. Epidemiol. 28, 169180 (2013).
  13. International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation (2014).
  14. Guariguata, L. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103, 137149 (2014).
  15. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation [online], (2013).
  16. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36, 10331046 (2013).
  17. Li, R. et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am. J. Manag. Care 19, 421430 (2013).
  18. Slabaugh, S. L., Curtis, B. H., Clore, G., Fu, H. & Schuster, D. P. Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US. J. Med. Econ. 18, 106112 (2015).
  19. Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260272 (2013).
  20. Ekundayo, O. J. et al. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am. J. Cardiol. 103, 8892 (2009).
  21. So, W. Y. et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29, 20462052 (2006).
  22. McCullough, P. A. et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am. Heart J. 156, 277283 (2008).
  23. Thomas, M. C. et al. Diabetic kidney disease. Nat. Rev. Dis. Primers 1, 15018 (2015).
  24. de Boer, I. H. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305, 25322539 (2011).
  25. Thomas, M. C., Weekes, A. J., Broadley, O. J., Cooper, M. E. & Mathew, T. H. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med. J. Aust. 185, 140144 (2006).
  26. Dwyer, J. P. et al. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med. 2, 110 (2012).
  27. Parving, H. H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 69, 20572063 (2006).
  28. Bailey, R. A., Wang, Y., Zhu, V. & Rupnow, M. F. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res. Notes 7, 415 (2014).
  29. Metsarinne, K. et al. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Prim. Care Diabetes 9, 3138 (2015).
  30. Hill, C. J. et al. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit. QJM 106, 933942 (2013).
  31. Low, S. K. et al. Prevalence of chronic kidney disease in adults with type 2 diabetes mellitus. Ann. Acad. Med. Singapore 45, 164171 (2015).
  32. Prasannakumar, M. et al. An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India). Indian J. Endocrinol. Metab. 19, 520523 (2015).
  33. Retnakaran, R. et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55, 18321839 (2006).
  34. Afghahi, H. et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes — the Swedish National Diabetes Register (NDR). Nephrol. Dial. Transplant. 26, 12361243 (2011).
  35. Bruno, G. et al. Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study. Diabetes Care 26, 23532358 (2003).
  36. Mogensen, C. E., Christensen, C. K. & Vittinghus, E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32, S64S78 (1983).
  37. Thomas, M. C. et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32, 14971502 (2009).
  38. Perkins, B. A. et al. Regression of microalbuminuria in type 1 diabetes. N. Eng. J. Med. 348, 22852293 (2003).
  39. Pugliese, G. et al. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr. Metab. Cardiovasc. Dis. 24, 815822 (2014).
  40. Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302308 (2013).
  41. MacIsaac, R. J. et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27, 195200 (2004).
  42. Ekinci, E. I. et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 36, 36203626 (2013).
  43. Kramer, H. J., Nguyen, Q. D., Curhan, G. & Hsu, C. Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289, 32733277 (2003).
  44. American Diabetes Association. Standards of medical care in diabetes — 2008. Diabetes Care 31, S12S54 (2008).
  45. Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diab. 32, S126S133 (2008).
  46. Kagoma, Y. K. et al. Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review. Am. J. Kidney Dis. 57, 592601 (2011).
  47. Bruno, G. et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 50, 941948 (2007).
  48. Glassock, R. J. & Winearls, C. The global burden of chronic kidney disease: how valid are the estimates? Nephron Clin. Pract. 110, c39c46; discussion c47 (2008).
  49. Glassock, R. J. Referrals for chronic kidney disease: real problem or nuisance? JAMA 303, 12011203 (2010).
  50. Vickers, J. A. & Sturdivant, R. L. Automated reporting of estimated glomerular filtration rate alters referral patterns to a nephrology clinic. Am. J. Med. Sci. 342, 218220 (2011).
  51. Foote, C. et al. Impact of estimated GFR reporting on late referral rates and practice patterns for end-stage kidney disease patients: a multilevel logistic regression analysis using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Am. J. Kidney Dis. 64, 359366 (2014).
  52. Polkinghorne, K. Controversies in chronic kidney disease staging. Clin. Biochem. Rev. 32, 5559 (2011).
  53. Grace, B. S., Clayton, P. & McDonald, S. P. Increases in renal replacement therapy in Australia and New Zealand: understanding trends in diabetic nephropathy. Nephrology 17, 7684 (2012).
  54. Yamagata, K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin. Exp. Nephrol. 12, 18 (2008).
  55. Atkins, R. C. & Zimmet, P. Diabetic kidney disease: act now or pay later. Kidney Int. 77, 375377 (2010).
  56. Forsblom, C. et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J. Am. Soc. Nephrol. 22, 537544 (2011).
  57. Andresdottir, G. et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 37, 16601667 (2014).
  58. Adler, A. I. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225232 (2003).
  59. Sakhuja, V. & Sud, K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int. 63, S115S118 (2003).
  60. Sheen, Y. J. & Sheu, W. H. Risks of rapid decline renal function in patients with type 2 diabetes. World J. Diabetes 5, 835846 (2014).
  61. Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010 N. Eng. J. Med. 370, 15141523 (2014).
  62. Sorensen, V. R., Hansen, P. M., Heaf, J. & Feldt-Rasmussen, B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int. 70, 187191 (2006).
  63. Carstensen, B., Kristensen, J. K., Ottosen, P., Borch-Johnsen, K. & Steering Group of the National Diabetes Register. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51, 21872196 (2008).
  64. Williams, M. E. Diabetic CKD/ESRD 2010: a progress report? Sem. Dial. 23, 129133 (2010).
  65. Comas, J. et al. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. Nephrol. Dial. Transplant. 28, 11911198 (2013).
  66. Harper, S. Economic and social implications of aging societies. Science 346, 587591 (2014).
  67. Jacobsen, L. A., Mather, M., Lee, M. & Kent, M. America's aging population. PRB [online], (2011).
  68. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2015 Revision, Key Findings and Advance Tables (United Nations, 2015).
  69. Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E. & Williamson, D. F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8, 29 (2010).
  70. National Centre for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States CDC [online], (2014).
  71. Formiga, F. et al. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet. Med. http:dx.doi.org/10.1111/dme.12894 (2015).
  72. Clase, C. M., Garg, A. X. & Kiberd, B. A. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 13, 13381349 (2002).
  73. D'Adamo, E. & Caprio, S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 34, S161S165 (2011).
  74. Azzopardi, P. et al. Type 2 diabetes in young Indigenous Australians in rural and remote areas: diagnosis, screening, management and prevention. Med. J. Aust. 197, 3236 (2012).
  75. Kevat, D., Wilson, D. & Sinha, A. A 5-year-old girl with type 2 diabetes. Lancet 383, 1268 (2014).
  76. Group, T. S. et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N. Eng. J. Med. 366, 22472256 (2012).
  77. Dart, A. B. et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 35, 12651271 (2012).
  78. Pinhas-Hamiel, O. & Zeitler, P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 369, 18231831 (2007).
  79. Yokoyama, H. et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 58, 302311 (2000).
  80. Nelson, R. G., Pavkov, M. E., Hanson, R. L. & Knowler, W. C. Changing course of diabetic nephropathy in the Pima Indians. Diabetes Res. Clin. Pract. 82, S10S14 (2008).
  81. Shanghai Diabetes Research Cooperative Group, Shanghai. Diabetes mellitus survey in Shanghai. Chin. Med. J. 93, 663672 (1980).
  82. Xu, Y. et al. Prevalence and control of diabetes in Chinese adults. JAMA 310, 948959 (2013).
  83. Kenealy, T. et al. Increased prevalence of albuminuria among non-European peoples with type 2 diabetes. Nephrol. Dial. Transplant. 27, 18401846 (2012).
  84. Chowdhury, T. A. & Lasker, S. S. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM 95, 241246 (2002).
  85. Burden, A. C., McNally, P. G., Feehally, J. & Walls, J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet. Med. 9, 641645 (1992).
  86. Chandie Shaw, P. K. et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 29, 13831385 (2006).
  87. Bruce, R., Williams, L. & Cundy, T. Rates of progression to end stage renal failure in nephropathy secondary to type 1 and type 2 diabetes mellitus. Aust. N. Z. J. Med. 24, 390395 (1994).
  88. Lanting, L. C., Joung, I. M., Mackenbach, J. P., Lamberts, S. W. & Bootsma, A. H. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care 28, 22802288 (2005).
  89. Lear, S. A. et al. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am. J. Clin. Nutr. 86, 353359 (2007).
  90. Nelson, R. G., Morgenstern, H. & Bennett, P. H. Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 47, 14891493 (1998).
  91. Lemley, K. V. A basis for accelerated progression of diabetic nephropathy in Pima Indians. Kidney Int. 63, S38S42 (2003).
  92. Nelson, R. G., Morgenstern, H. & Bennett, P. H. Birth weight and renal disease in Pima Indians with type 2 diabetes mellitus. Am. J. Epidemiol. 148, 650656 (1998).
  93. Singh, G. R. & Hoy, W. E. Kidney volume, blood pressure, and albuminuria: findings in an Australian aboriginal community. Am. J. Kidney Dis. 43, 254259 (2004).
  94. Hoerger, T. J., Segel, J. E., Gregg, E. W. & Saaddine, J. B. Is glycemic control improving in U.S. adults? Diabetes Care 31, 8186 (2008).
  95. Imperatore, G. et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971–2000. Am. J. Epidemiol. 160, 531539 (2004).
  96. Tseng, L. N. et al. Prevalence of hypertension and dyslipidemia and their associations with micro- and macrovascular diseases in patients with diabetes in Taiwan: an analysis of nationwide data for 2000–2009 J. Formos. Med. Assoc. 111, 625636 (2012).
  97. Emdin, C. A. et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313, 603615 (2015).
  98. Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169 (2011).
  99. Derby, L., Warram, J. H., Laffel, L. M. & Krolewski, A. S. Elevated blood pressure predicts the development of persistent proteinuria in the presence of poor glycemic control, in patients with type I diabetes. Diabete Metab. 15, 320326 (1989).
  100. Schmitz, A., Vaeth, M. & Mogensen, C. E. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 37, 12511258 (1994).
  101. Tanaka, Y. et al. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 21, 116120 (1998).
  102. Tolonen, N. et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia 52, 25222530 (2009).
  103. Thomas, M. C. et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29, 317322 (2006).
  104. Penno, G. et al. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS ONE 10, e0125512 (2015).
  105. Sacks, F. M. et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129, 9991008 (2014).
  106. Kaysen, G. A. Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int. 70, S55S58 (2006).
  107. de Vries, A. P. et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417426 (2014).
  108. Jun, M. et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 60, 20612071 (2012).
  109. Griffin, S. J. et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378, 156167 (2011).
  110. Haynes, R. et al. Effects of lowering LDL cholesterol on progression of kidney disease. J. Am. Soc. Nephrol. 25, 18251833 (2014).
  111. de Zeeuw, P. D. et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 3, 181190 (2015).
  112. Leibson, C. L. et al. Temporal trends in BMI among adults with diabetes. Diabetes Care 24, 15841589 (2001).
  113. Sharma, K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 76, 145148 (2009).
  114. Tsuboi, N., Utsunomiya, Y. & Hosoya, T. Obesity-related glomerulopathy and the nephron complement. Nephrol. Dial. Transplant. 28, iv108iv113 (2013).
  115. Look, A. R. G. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2, 801809 (2014).
  116. Carlsson, L. M. et al. The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial. Int. J. Obes. 39, 169175 (2015).
  117. Ford, E. S. et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000 N. Engl. J. Med. 356, 23882398 (2007).
  118. Yashkin, A. P., Picone, G. & Sloan, F. Causes of the change in the rates of mortality and severe complications of diabetes mellitus: 1992–2012. Med. Care 53, 268275 (2015).
  119. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117171 (2015).
  120. Schroeder, E. B. et al. Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM Project, 2005–2011. J. Diabetes Complications 29, 637643 (2015).
  121. Nelson, R. G. et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81, 987995 (1990).
  122. Andresdottir, G. et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 37, 16601667 (2014).
  123. Thomas, M. C. & Groop, P. H. New approaches to the treatment of nephropathy in diabetes. Expert Opin. Investig. Drugs 20, 10571071 (2011).
  124. Anand, S., Bitton, A. & Gaziano, T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS ONE 8, e72860 (2013).
  125. Chen, L., Magliano, D. J. & Zimmet, P. Z. The worldwide epidemiology of type 2 diabetes mellitus — present and future perspectives. Nat. Rev. Endocrinol. 8, 228236 (2012).
  126. Ejerblad, E. et al. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 17, 16951702 (2006).
  127. Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R. & Brancati, F. L. hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N. Eng. J. Med. 342, 905912 (2000).
  128. Lago, R. M., Singh, P. P. & Nesto, R. W. Diabetes and hypertension. Nat. Clin. Pract. Endocrinol. Metab. 3, 667 (2007).
  129. Beckles, G. L. & Chou, C. F. Diabetes — United States, 2006 and 2010. CDC [online], (2013).
  130. Hu, F. B. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34, 12491257 (2011).
  131. Misra, A., Ramchandran, A., Jayawardena, R., Shrivastava, U. & Snehalatha, C. Diabetes in South Asians. Diabet. Med. 31, 11531162 (2014).
  132. Derose, S. F. et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J. Kidney Dis. 62, 236244 (2013).
  133. Bryson, C. L., Ross, H. J., Boyko, E. J. & Young, B. A. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J. Kidney Dis. 48, 720726 (2006).
  134. Farag, Y. M., Kari, J. A. & Singh, A. K. Chronic kidney disease in the Arab world: a call for action. Nephron Clin. Pract. 121, c120c123 (2012).
  135. Tarver-Carr, M. E. et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J. Am. Soc. Nephrol. 13, 23632370 (2002).

Download references

Author information

Affiliations

  1. Baker IDI Heart & Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia.

    • Merlin C. Thomas,
    • Mark E. Cooper &
    • Paul Zimmet

Contributions

M.C.T. researched the data for the article. M.C.T. and P.Z. provided substantial contribution to discussions of the content and contributed equally to writing the article. All authors contributed equally to review and/or editing of the manuscript before submission.

Competing interests statement

M.C.T. has received honoraria for educational meetings conducted on behalf of Abbvie, Boehringer–Ingelheim, Eli-Lilly, Merck Sharpe and Dohme, Servier, Novartis, Takeda, Abbot, Allergan, and AstraZeneca. P.Z. has acted as an adviser and received honoraria for speaking on behalf of Eli-Lilly, Novo Nordisk, Haptocure (Israel), Janssen Cilag, and Sanofi Aventis. M.E.C. has received honoraria and consulting fees from Abbvie, Bayer, Boehringer–Ingelheim, Eli-Lilly, Merck, Servier, Takeda, Novo-Nordisk, and AstraZeneca as well as research grants from Novo-Nordisk and Abbvie.

Corresponding author

Correspondence to:

Author details

  • Merlin C. Thomas

    Professor Merlin Thomas is an NHMRC senior research fellow, physician, and scientist working at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He is a specialist in nephrology and endocrinology with a special research interest in chronic kidney disease associated with diabetes mellitus, its epidemiology and management.

  • Mark E. Cooper

    Professor Mark Cooper is the Chief Scientific Officer of the Baker IDI Heart and Diabetes Institute and Director of the JDRF Centre for Diabetes Complications at the Baker IDI Heart & Diabetes Institute. He holds honorary appointments as a Professor of Medicine at both Monash University and University of Melbourne. He is a trained endocrinologist with an appointment at the co-located Alfred Hospital.

  • Paul Zimmet

    Professor Paul Zimmet is emeritus director of the Baker IDI Heart and Diabetes Institute and founding director of the International Diabetes Institute before its merger with the Baker IDI Institute. He is an Adjunct Professor at Monash University, is a Patron of Obesity Australia, and Honorary President of the International Diabetes Federation. He is a member of the WHO expert panel on diabetes mellitus.

Additional data